Recombinant
Recombinant production of Hia protein, in full-length and N-terminally truncated forms, of non-typeable strains of Haemophilus influenzae , is described. The nucleic acid and deduced amino acid sequences of Hia genes of various strains of non-typeable and type c Haemophilus influenzae also are described.
1. An immunogenic composition comprising a recombinant Haemophilus influenzae adhesion (Hia) protein of non-typeable strain 33 encoded by SEQ ID.: 23, and a pharmaceutically acceptable carrier therefor.
2. The immunogenic composition of claim 1 formulated as a vaccine for in vivo administration such that, upon administration of the composition to a host, the host is protected against disease caused by Haemophilus influenzae non-typeable strain 33.
3. The immunogenic composition of claim 1 formulated as a microparticle, capsule or liposome preparation.
4. The immunogenic composition of claim 1 further comprising an adjuvant.
5. A method for inducing protection against disease caused by Haemophilia influenzae non-typeable strain 33, comprising administering to a susceptible host an effective amount of the immunogenic composition of claim 1 .
6. The method of claim 5 wherein the susceptible host is a human.
7. An immunogenic composition comprising a recombinant Haemophilia influenzae adhesion (Hia) protein of non-typeable strain 33 having the amino acid sequence of SEQ ID NO: 24, and a pharmaceutically acceptable carrier therefor.
8. The immunogenic composition of claim 7 formulated as a vaccine for in vivo administration such that, upon administration of the composition to a host, the host is protected against disease caused by Haemophilus influenzae non-typeable strain 33.
9. The immunogenic composition of claim 7 formulated as a microparticle, capsule or liposome preparation.
10. The immunogenic composition of claim 7 further comprising an adjuvant.
11. A method for inducing protection against disease caused by Haemophilus influenzae non-typeable strain 33, comprising administering to a susceptible host an effective amount of the immunogenic composition of claim 7 .
12. The method of claim 11 wherein the susceptible host is a human.
13. An immunogenic composition comprising a truncated recombinant Haemophilia influenzae adhesion (Hia) protein of non-typeable strain 33 having the amino acid sequence of SEQ. ID NO.: 24, beginning at valine 38.
14. The immunogenic composition of claim 13 formulated as a vaccine for in vivo administration such that, upon administration of the composition to a host, the host is protected against disease caused by Haemophilus influenzae non-typeable strain 33.
15. The immunogenic composition of claim 13 formulated as a microparticle, capsule or liposome preparation.
16. The immunogenic composition of claim 13 further comprising an adjuvant.
17. A method for inducing, protection against disease caused by Haemophilus influenzae non-typeable strain 33, comprising administering to a susceptible host an effective amount of the immunogenic composition of claim 13 .
18. The method of claim 17 wherein the susceptible host is a human.